TABLE 1.
Preoperative patient characteristics and presentation (n = 282)
| Age (mean ± SD) | 54.9 (±11.5) |
| BMI (median, range) (n = 234) | 27 (16–59) |
| Preoperative albumin (median, range) (n = 210) | 3.9 (0.7–5.8) |
| Preoperative CA19-9 (median, range) (n = 111) | 26.9 (0.9–22797) |
| Preoperative CEA (median, range) (n = 157) | 5.9 (0.4–901.9) |
| Preoperative CA-125 (median, range) (n = 106) | 29.6 (2.9–381.7) |
| Gender (n, %) | |
| Male | 141 (50) |
| Female | 141 (50) |
| Race (n, %) | |
| White | 259 (91.8) |
| Not white | 10 (3.6) |
| Unknown | 13 (4.6) |
| Disease status (n, %) | |
| Primary | 134 (47.5) |
| Recurrent | 137 (48.6) |
| Unknown | 11 (3.9) |
| ASA (n, %) | |
| 1 | 2 (0.7) |
| 2 | 35 (12.4) |
| 3 | 124 (44) |
| 4 | 28 (9.9) |
| Unknown | 93 (33) |
| Prior surgical therapy (n, %) | |
| Cytoreductive surgery (CRS) (N = 270) | 92 (34.1) |
| Chemoperfusion (N = 276) | 21 (7.6) |
| Clinical parameters (n, %) | |
| Abdominal pain | 146 (51.8) |
| Ascites | 101 (35.8) |
| Bowel obstruction | 35 (12.4) |
| Gastrointestinal bleeding | 9 (3.2) |
| Intestinal perforation | 23 (8.2) |
| Extra abdominal disease | 29 (10.3) |
| Prior chemotherapy (n = 109) | |
| Prior adjuvant | 67 (61.5) |
| Prior neoadjuvant or definitive | 31 (28.4) |
| Unknown | 11 (10.1) |
BMI body mass index, ASA American society of anesthesiology